drugset / Trial / NCT05101135

To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

NCT05101135

Phase 3 Unknown 256 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of JT-001 Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin.

Timeline

Start
2021-11-17
Primary completion
2022-10-31
Completion
2022-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JT001 Small molecule 15 mg